OBJECTIVES: We aimed to determine whether syringe exchange programs (SEPs) currently receive or anticipate pursuing federal funding and barriers to funding applications following the recent removal of the long-standing ban on using federal funds for SEPs. METHODS: We conducted a telephone-administered cross-sectional survey of US SEPs. Descriptive statistics summarized responses; bivariate analyses examined differences in pursuing funding and experiencing barriers by program characteristics. RESULTS: Of the 187 SEPs (92.1%) that responded, 90.9% were legally authorized. Three received federal funds and 116 intended to pursue federal funding. Perceived federal funding barriers were common and included availability and accessibility of funds, legal requirements such as written police support, resource capacity to apply and comply with funding regulations, local political and structural organization, and concern around altering program culture. Programs without legal authorization, health department affiliation, large distribution, or comprehensive planning reported more federal funding barriers. CONCLUSIONS: Policy implementation gaps appear to render federal support primarily symbolic. In practice, funding opportunities may not be available to all SEPs. Increased technical assistance and legal reform could improve access to federal funds, especially for SEPs with smaller capacity and tenuous local support.
OBJECTIVES: We aimed to determine whether syringe exchange programs (SEPs) currently receive or anticipate pursuing federal funding and barriers to funding applications following the recent removal of the long-standing ban on using federal funds for SEPs. METHODS: We conducted a telephone-administered cross-sectional survey of US SEPs. Descriptive statistics summarized responses; bivariate analyses examined differences in pursuing funding and experiencing barriers by program characteristics. RESULTS: Of the 187 SEPs (92.1%) that responded, 90.9% were legally authorized. Three received federal funds and 116 intended to pursue federal funding. Perceived federal funding barriers were common and included availability and accessibility of funds, legal requirements such as written police support, resource capacity to apply and comply with funding regulations, local political and structural organization, and concern around altering program culture. Programs without legal authorization, health department affiliation, large distribution, or comprehensive planning reported more federal funding barriers. CONCLUSIONS: Policy implementation gaps appear to render federal support primarily symbolic. In practice, funding opportunities may not be available to all SEPs. Increased technical assistance and legal reform could improve access to federal funds, especially for SEPs with smaller capacity and tenuous local support.
Authors: D Vlahov; D C Des Jarlais; E Goosby; P C Hollinger; P G Lurie; M D Shriver; S A Strathdee Journal: Am J Epidemiol Date: 2001-12-15 Impact factor: 4.897
Authors: Scott Burris; Alexander C Wagenaar; Jeffrey Swanson; Jennifer K Ibrahim; Jennifer Wood; Michelle M Mello Journal: Milbank Q Date: 2010-06 Impact factor: 4.911
Authors: Samuel R Friedman; Barbara Tempalski; Hannah Cooper; Theresa Perlis; Marie Keem; Risa Friedman; Peter L Flom Journal: J Urban Health Date: 2004-09 Impact factor: 3.671
Authors: Eric T Roberts; Samuel R Friedman; Joanne E Brady; Enrique R Pouget; Barbara Tempalski; Sandro Galea Journal: Drug Alcohol Depend Date: 2009-09-12 Impact factor: 4.492
Authors: Leo Beletsky; Jess Cochrane; Anne L Sawyer; Chris Serio-Chapman; Marina Smelyanskaya; Jennifer Han; Natanya Robinowitz; Susan G Sherman Journal: Am J Public Health Date: 2015-07-16 Impact factor: 9.308
Authors: Jesse L Goldshear; Kelsey A Simpson; Alex H Kral; Lynn D Wenger; Ricky N Bluthenthal Journal: Subst Use Misuse Date: 2021-03-26 Impact factor: 2.362
Authors: Beth E Meyerson; Carrie A Lawrence; Summer Dawn Cope; Steven Levin; Christopher Thomas; Lori Ann Eldridge; Haley B Coles; Nina Vadiei; Amy Kennedy Journal: Harm Reduct J Date: 2019-09-18
Authors: Traci C Green; Thomas Stopka; Ziming Xuan; Tyler C Davis; Jesse Boggis; Adriane N Irwin; Mary Gray; Daniel M Hartung; Jeffrey Bratberg Journal: J Am Pharm Assoc (2003) Date: 2021-03-11